This company has been acquired
BLU Stock Overview
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BELLUS Health Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$19.50 |
| 52 Week High | CA$19.90 |
| 52 Week Low | CA$8.58 |
| Beta | -0.28 |
| 1 Month Change | -1.42% |
| 3 Month Change | 100.82% |
| 1 Year Change | 50.70% |
| 3 Year Change | 38.79% |
| 5 Year Change | 962.09% |
| Change since IPO | -97.95% |
Recent News & Updates
Recent updates
BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans
Jan 16
Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation
Sep 07We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely
May 05Here's Why We're Watching BELLUS Health's (TSE:BLU) Cash Burn Situation
Jan 06Companies Like BELLUS Health (TSE:BLU) Are In A Position To Invest In Growth
Sep 10Shareholder Returns
| BLU | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0.5% | -5.8% | -0.6% |
| 1Y | 50.7% | -37.3% | 3.9% |
Return vs Industry: BLU exceeded the Canadian Biotechs industry which returned 23.5% over the past year.
Return vs Market: BLU exceeded the Canadian Market which returned 0.8% over the past year.
Price Volatility
| BLU volatility | |
|---|---|
| BLU Average Weekly Movement | 28.1% |
| Biotechs Industry Average Movement | 13.6% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: BLU's share price has been volatile over the past 3 months.
Volatility Over Time: BLU's weekly volatility has increased from 16% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 74 | Roberto Bellini | www.bellushealth.com |
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada.
BELLUS Health Inc. Fundamentals Summary
| BLU fundamental statistics | |
|---|---|
| Market cap | CA$2.47b |
| Earnings (TTM) | -CA$115.02m |
| Revenue (TTM) | CA$19.88k |
Over9,999x
P/S Ratio-21.5x
P/E RatioIs BLU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLU income statement (TTM) | |
|---|---|
| Revenue | US$15.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$15.00k |
| Other Expenses | US$86.80m |
| Earnings | -US$86.79m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.68 |
| Gross Margin | 100.00% |
| Net Profit Margin | -578,586.67% |
| Debt/Equity Ratio | 0% |
How did BLU perform over the long term?
See historical performance and comparison